



RESEARCH ACCOMPLISHMENTS



MAY 2022

PUBLICATIONS:

Shah B, Dong X. Design and Evaluation of Two-Step Biorelevant Dissolution Methods for Docetaxel Oral Formulations. *AAPS PharmSciTech*. 2022 Apr 19; 23(5):113. doi: 10.1208/s12249-022-02256-2. PMID: 35441281.

Escandon P, Liu A, Nicholas SE, Khan A, Riaz KM, Karamichos D. Unravelling Novel Roles of Salivary Exosomes in the Regulation of Human Corneal Stromal Cell Migration and Wound Healing. *Int J Mol Sci*. 2022 Apr 14; 23(8):4330. doi: 10.3390/ijms23084330. PMID: 35457149.

Zuo Z, Babu K, Ganguly C, Zolekar A, Newsom S, Rajan R, Wang YC, Liu J. Rational Engineering of CRISPR-Cas9 Nuclease to Attenuate Position-Dependent Off-Target Effects. *CRISPR J*. 2022 Apr; 5(2):329-340. doi: 10.1089/crispr.2021.0076. PMID: 35438515.

Zalmai R, Agbor Bawa W, Howard M, Rasu RS. Assessing Co-prescription of Opioids with Central Nervous System Depressants for Nonmalignant Chronic Musculoskeletal Pain Management in the Outpatient Setting. *Journal of Opioid Management* 2022 Mar-Apr; 18(2):107-122. doi: 10.5055/jom.2022.0701. PMID: 35476880.

Wang H, Manning SE, Ho AF, Sambamoorthi U. Factors Associated with Reducing Disparities in Electronic Personal Health Records Use Among Non-Hispanic White and Hispanic Adults. *J Racial Ethn Health Disparities*. 2022 Apr 27. doi: 10.1007/s40615-022-01307-5. Online ahead of print. PMID: 35476224.

PRESENTATIONS:

(None reported)

VIRTUAL POSTER PRESENTATIONS:

(None reported)

GRANTS/CONTRACTS AWARDED:

William Weiss — Industry Sponsored Project; \$452,620.34; Efficacy of a therapeutic candidate in the Neutropenic Rabbit Lung Infection Model with *K. pneumoniae*, *P. aeruginosa* and *A. baumannii*; 4/7/22 – 4/6/23. Industry Sponsored Project; \$211,790.75; Efficacy and Pharmacokinetics in the murine neutropenic thigh infection and murine neutropenic lung infection models with *A. baumannii* and/or *P. aeruginosa*; 2/8/22 – 2/7/23. Industry Sponsored Project; \$47,052.48; Evaluation of mRNA Isotypes in *P. aeruginosa* Lung Challenge Studies; 4/7/22 – 4/6/23. Industry Sponsored Project; \$24,104.44; Efficacy of Novel Antibacterial Test Articles in the Rat Pneumonia Model; 4/22/22 – 4/21/23. Industry Sponsored Project; \$19,695.66; Development of an ELISA assay for the determination of levels of a therapeutic candidate in rat plasma and bronchoalveolar lavage fluid; 4/5/22 – 4/4/23. Industry Sponsored Project; \$8,941.00; Immunogenicity assessment of a peptide immunogen in naïve mice – adjuvant screening; 2/21/22 – 2/20/23. Industry Sponsored Project; \$8,642.00; Immunogenicity assessment of a peptide immunogen in naïve mice – adjuvant screening; 1/6/22 – 1/5/23. Industry Sponsored Project; \$8,332.00; Establishment of a rat experimental acute otitis media model in rats; 2/14/22 – 2/13/23. Industry Sponsored Project; \$4,458.20; Establishment of the LD50 for a select *E. coli* in the mouse peritonitis infection model; 4/25/22 – 4/24/23.

Hongli Wu — TCU / NIGMS; \$53,496.00; Building Better Antioxidants: Virtual Screening, Synthesis, and Characterization of Multifunctional Small Molecules Combining Nrf2 Pathway Activation and Direct Antioxidant Activity; 2/1/22 – 1/31/25.